Clinical trials: PAH
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Assessment of Six-minute Walking Distance Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on six-minute walking distance and other scores in patients with pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Six-minute Walk Test, NYHA
- Trial name
- NCT07797166
- Testing
- Re-Ascent sea level to 2850m
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3)
Nailfold Capillaroscopy in PH
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3), Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT07768644
- Testing
- Standard of Care therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Glasgow
Pulmonary Arterial Hypertension (PAH)
Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by increased pressure in the pulmonary arteries, leading to right heart failure and premature death.
- Trial name
- ASCEND-PAH (NCT07713914)
- Testing
- Prostacyclin Pathway Agent, Sildenafil Dose Optimization
- Where
- Brazil
- Volunteers
- 196 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension (PAH)
TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends
TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension…
- Trial name
- NCT07736846
- Testing
- treprostinil
- Volunteers
- 300 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
What is the Role of the Exposome in Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a rare and incurable disease affecting people of all ages. It is characterized by obstructive remodeling of the small pulmonary arteries, responsible for an increase in pulmonary arterial…
- Trial name
- EXPOSPAH (NCT07172334)
- Testing
- Questionnaires, Samples
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- Poitiers University Hospital
Pulmonary Arterial Hypertension PAH
A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy
- Trial name
- NCT07593027
- Testing
- IMC-003 and PAH background therapy
- Where
- 29 sites in China
- Volunteers
- 120 people
- Sponsor
- ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Pulmonary Arterial Hypertension PAH
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk…
- Trial name
- NCT06477640
- Testing
- Exercise, Standard of Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Rochester
PAH
TSPO Endothelial - EMPATHY
The aim of the study is to investigate whether the cells which line the blood vessels (called "endothelial cells") are involved in the processes which contribute to Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT07697183
- Testing
- XBD173
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Imperial College London
PAH
Impact of an Optimized Omega-3 Formulation on Inflammation and Endothelial Dysfunction in Pulmonary Arterial Hypertension
The objective of this research project is to evaluate the biological effects of long-chain omega-3 supplementation, administered in an optimized, high-purity formulation (EPA:DHA 6:1, >95% v/v), as an adjunct to standard-of-care…
- Trial name
- OMEGA-PAH (NCT07697235)
- Testing
- OMega 3
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Arterial Hypertension (PAH)
Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets
An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram…
- Trial name
- NCT07694128
- Testing
- Selexipag Film Coated Tablets (T1), Selexipag Film Coated Tablets (T2), Uptravi® (selexipag) film coated tablets
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially life-threatening disease characterized by pulmonary vascular remodeling, increased pulmonary vascular resistance, and right ventricular dysfunction.
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
- Trial name
- ACTION (NCT07013149)
- Testing
- Switch from Ambrisentan to Bosentan, Maintenance of Ambrisentan Therapy
- Where
- Brazil
- Volunteers
- 183 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Vasopressor Agents in Pulmonary Hypertension Crisis
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by…
- Conditions
- Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Hypertension, Pulmonary
- Trial name
- NCT07667829
- Testing
- Norepinephrine, Dopamine, Epinephrine
- Where
- 3 sites in China
- Volunteers
- 75 people
- Sponsor
- China National Center for Cardiovascular Diseases
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by structural changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and elevated pulmonary arterial pressure and…
- Trial name
- SOFAPI (NCT07357974)
- Testing
- [68Ga]Ga-FAPI PET/CT, [68Ga]Ga-MAA PET/CT
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Brest
Pulmonary Arterial Hypertension (PAH)
Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.
- Trial name
- NCT07632898
- Testing
- IKT-001
- Volunteers
- 484 people
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Arterial Hypertension (PAH)
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class…
- Trial name
- ATHENA (NCT07601295)
- Testing
- Tiprelestat (5 mg), Tiprelestat (10 mg)
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension (PAH), Comorbidities
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
Pulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Comorbidities, Cardiovascular Disease (CVD)
- Trial name
- COMMODITIES (NCT07245680)
- Testing
- Tadalafil, Ambrisentan
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension (PAH)
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
- Trial name
- (STOP-PAH) (NCT06872112)
- Testing
- Artesunate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joseph C. Wu
Congenital Heart Disease (CHD), Eisenmenger Syndrome
Sota-ES - Sotatercept in Patients With Congenital Heart Disease and Eisenmenger´s Syndrome
The present study seeks to provide pilot data on the safety and efficacy of medical therapy with sotatercept in patients with an established diagnosis of congenital heart disease and Eisenmenger syndrome.
- Conditions
- Congenital Heart Disease (CHD), Eisenmenger Syndrome, PAH
- Trial name
- CHASE (NCT07498803)
- Testing
- Sotatercept
- Volunteers
- 40 people
- Sponsor
- Philipps University Marburg